Charlotte J Tutein Nolthenius1,2, Thierry N Boellaard1, Margriet C de Haan3, C Yung Nio1, Maarten G J Thomeer4, Shandra Bipat1, Alexander D Montauban van Swijndregt2, Marc J van de Vijver5, Katharina Biermann6, Ernst J Kuipers7,8, Evelien Dekker9, Jaap Stoker1. 1. Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 2. Department of Radiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 3. Department of Radiology, University Medical Center, Utrecht, The Netherlands. 4. Department of Radiology, Erasmus University Medical Center, Rotterdam, The Netherlands. 5. Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 6. Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands. 7. Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands. 8. Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 9. Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
OBJECTIVES: Volumetric growth assessment has been proposed for predicting advanced histology at surveillance computed tomography (CT) colonography (CTC). We examined whether is it possible to predict which small (6-9 mm) polyps are likely to become advanced adenomas at surveillance by assessing volumetric growth. METHODS: In an invitational population-based CTC screening trial, 93 participants were diagnosed with one or two 6-9 mm polyps as the largest lesion(s). They were offered a 3-year surveillance CTC. Participants in whom surveillance CTC showed lesion(s) of ≥6 mm were offered colonoscopy. Volumetric measurements were performed on index and surveillance CTC, and polyps were classified into growth categories according to ±30% volumetric change (>30% growth as progression, 30% growth to 30% decrease as stable, and >30% decrease as regression). Polyp growth was related to histopathology. RESULTS: Between July 2012 and May 2014, 70 patients underwent surveillance CTC after a mean surveillance interval of 3.3 years (s.d. 0.3; range 3.0-4.6 years). In all, 33 (35%) of 95 polyps progressed, 36 (38%) remained stable, and 26 (27%) regressed, including an apparent resolution in 13 (14%) polyps. In 68 (83%) of the 82 polyps at surveillance, histopathology was obtained; 15 (47%) of 32 progressing polyps were advanced adenomas, 6 (21%) of 28 stable polyps, and none of the regressing polyps. CONCLUSIONS: The majority of 6-9 mm polyps will not progress to advanced neoplasia within 3 years. Those that do progress to advanced status can in particular be found among the lesions that increased in size on surveillance CTC.
OBJECTIVES: Volumetric growth assessment has been proposed for predicting advanced histology at surveillance computed tomography (CT) colonography (CTC). We examined whether is it possible to predict which small (6-9 mm) polyps are likely to become advanced adenomas at surveillance by assessing volumetric growth. METHODS: In an invitational population-based CTC screening trial, 93 participants were diagnosed with one or two 6-9 mm polyps as the largest lesion(s). They were offered a 3-year surveillance CTC. Participants in whom surveillance CTC showed lesion(s) of ≥6 mm were offered colonoscopy. Volumetric measurements were performed on index and surveillance CTC, and polyps were classified into growth categories according to ±30% volumetric change (>30% growth as progression, 30% growth to 30% decrease as stable, and >30% decrease as regression). Polyp growth was related to histopathology. RESULTS: Between July 2012 and May 2014, 70 patients underwent surveillance CTC after a mean surveillance interval of 3.3 years (s.d. 0.3; range 3.0-4.6 years). In all, 33 (35%) of 95 polyps progressed, 36 (38%) remained stable, and 26 (27%) regressed, including an apparent resolution in 13 (14%) polyps. In 68 (83%) of the 82 polyps at surveillance, histopathology was obtained; 15 (47%) of 32 progressing polyps were advanced adenomas, 6 (21%) of 28 stable polyps, and none of the regressing polyps. CONCLUSIONS: The majority of 6-9 mm polyps will not progress to advanced neoplasia within 3 years. Those that do progress to advanced status can in particular be found among the lesions that increased in size on surveillance CTC.
Authors: Srinath C Yeshwant; Ronald M Summers; Jianhua Yao; Daniel S Brickman; J Richard Choi; Perry J Pickhardt Journal: Radiology Date: 2006-12 Impact factor: 11.105
Authors: Michael E Zalis; Matthew A Barish; J Richard Choi; Abraham H Dachman; Helen M Fenlon; Joseph T Ferrucci; Seth N Glick; Andrea Laghi; Michael Macari; Elizabeth G McFarland; Martina M Morrin; Perry J Pickhardt; Jorge Soto; Judy Yee Journal: Radiology Date: 2005-07 Impact factor: 11.105
Authors: C Hassan; P J Pickhardt; D H Kim; E Di Giulio; A Zullo; A Laghi; A Repici; F Iafrate; J Osborn; B Annibale Journal: Aliment Pharmacol Ther Date: 2009-10-08 Impact factor: 8.171
Authors: Esther M Stoop; Margriet C de Haan; Thomas R de Wijkerslooth; Patrick M Bossuyt; Marjolein van Ballegooijen; C Yung Nio; Marc J van de Vijver; Katharina Biermann; Maarten Thomeer; Monique E van Leerdam; Paul Fockens; Jaap Stoker; Ernst J Kuipers; Evelien Dekker Journal: Lancet Oncol Date: 2011-11-15 Impact factor: 41.316
Authors: Perry J Pickhardt; David H Kim; B Dustin Pooler; J Louis Hinshaw; Duncan Barlow; Don Jensen; Mark Reichelderfer; Brooks D Cash Journal: Lancet Oncol Date: 2013-06-07 Impact factor: 41.316
Authors: R J Schlemper; R H Riddell; Y Kato; F Borchard; H S Cooper; S M Dawsey; M F Dixon; C M Fenoglio-Preiser; J F Fléjou; K Geboes; T Hattori; T Hirota; M Itabashi; M Iwafuchi; A Iwashita; Y I Kim; T Kirchner; M Klimpfinger; M Koike; G Y Lauwers; K J Lewin; G Oberhuber; F Offner; A B Price; C A Rubio; M Shimizu; T Shimoda; P Sipponen; E Solcia; M Stolte; H Watanabe; H Yamabe Journal: Gut Date: 2000-08 Impact factor: 23.059
Authors: M H Liedenbaum; M J Denters; F M Zijta; V F van Ravesteijn; S Bipat; F M Vos; E Dekker; J Stoker Journal: Clin Radiol Date: 2010-09-29 Impact factor: 2.350
Authors: Perry J Pickhardt; Bryan Dustin Pooler; David H Kim; Cesare Hassan; Kristina A Matkowskyj; Richard B Halberg Journal: Gastroenterol Clin North Am Date: 2018-06-29 Impact factor: 3.806
Authors: Meta C J van Lanschot; Beatriz Carvalho; Veerle M H Coupé; Manon van Engeland; Evelien Dekker; Gerrit A Meijer Journal: BMC Cancer Date: 2017-02-07 Impact factor: 4.430
Authors: Melanie M Ivancic; Leigh W Anson; Perry J Pickhardt; Bryant Megna; Bryan D Pooler; Linda Clipson; Mark Reichelderfer; Michael R Sussman; William F Dove Journal: Proc Natl Acad Sci U S A Date: 2019-04-10 Impact factor: 11.205